Manumycin A, inhibitor of ras farnesyltransferase, inhibits proliferation and migration of rat vascular smooth muscle cells

被引:45
作者
Kouchi, H
Nakamura, K
Fushimi, K
Sakaguchi, M
Miyazaki, M
Ohe, T
Namba, M
机构
[1] Okayama Univ, Sch Med, Dept Cardiovasc Med, Okayama 7008558, Japan
[2] Okayama Univ, Sch Med, Dept Cell Biol, Okayama 7008558, Japan
关键词
D O I
10.1006/bbrc.1999.1546
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Restenosis after angioplasty is thought to be caused by proliferation and migration of vascular smooth muscle cells (VSMCs), and it is a most serious problem in medical treatment. A low dose (50 ng/ml) of manumycin A, an inhibitor of p21(ras) (ras) farnesylation, significantly inhibited proliferation of rat VSMCs stimulated by the platelet-derived growth factor (PDGF). The mitoinhibitory effect of manumycin A was dose- and time-dependent but was independent of cell density. Western blot analysis showed that manumycin A reduced the amount of functional ras localized at the cytoplasmic membrane and inhibited the phosphorylation of p42/44 mitogen-activated protein kinase (MAPK). Manumycin A also inhibited VSMC migration and disorganized alpha actin fibers, as shown by immnofluorecence staining. These results indicate that the interruption of the ras/MAPK signal transduction pathway and the disorganization of alpha actin fibers are the main cause of manumycin A inhibition of VSMC proliferation and migration induced by PDGF. (C) 1999 Academic Press.
引用
收藏
页码:915 / 920
页数:6
相关论文
共 26 条
[1]
SPHINGOSINE-1-PHOSPHATE INHIBITS PDGF-INDUCED CHEMOTAXIS OF HUMAN ARTERIAL SMOOTH-MUSCLE CELLS - SPATIAL AND TEMPORAL-MODULATION OF PDGF CHEMOTACTIC SIGNAL-TRANSDUCTION [J].
BORNFELDT, KE ;
GRAVES, LM ;
RAINES, EW ;
IGARASHI, Y ;
WAYMAN, G ;
YAMAMURA, S ;
YATOMI, Y ;
SIDHU, JS ;
KREBS, EG ;
HAKOMORI, S ;
ROSS, R .
JOURNAL OF CELL BIOLOGY, 1995, 130 (01) :193-206
[2]
Cell cycle progression - New therapeutic target for vascular proliferative disease [J].
Braun-Dullaeus, RC ;
Mann, MJ ;
Dzau, VJ .
CIRCULATION, 1998, 98 (01) :82-89
[3]
Local drug delivery systems and prevention of restenosis [J].
Brieger, D ;
Topol, E .
CARDIOVASCULAR RESEARCH, 1997, 35 (03) :405-413
[4]
SMOOTH-MUSCLE CELL IN CULTURE [J].
CHAMLEYCAMPBELL, J ;
CAMPBELL, GR ;
ROSS, R .
PHYSIOLOGICAL REVIEWS, 1979, 59 (01) :1-61
[5]
MODULATION OF GELSOLIN CONTENT IN RAT AORTIC SMOOTH-MUSCLE CELLS DURING DEVELOPMENT, EXPERIMENTAL INTIMAL THICKENING AND CULTURE - AN IMMUNOHISTOCHEMICAL AND BIOCHEMICAL-STUDY [J].
CHAPONNIER, C ;
KOCHER, O ;
GABBIANI, G .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1990, 190 (03) :559-565
[6]
Management of restenosis after coronary intervention [J].
Dangas, G ;
Fuster, V .
AMERICAN HEART JOURNAL, 1996, 132 (02) :428-436
[7]
DER CJ, 1991, CANCER CELL-MON REV, V3, P331
[8]
Engel L, 1997, IN VITRO CELL DEV-AN, V33, P443
[9]
LONG-TERM HISTOLOGIC PATENCY AFTER PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY IS PREDICTED BY THE CREATION OF A GREATER LUMEN AREA [J].
FARB, A ;
VIRMANI, R ;
ATKINSON, JB ;
ANDERSON, PG .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1994, 24 (05) :1229-1235
[10]
INHIBITION OF NEOINTIMAL SMOOTH-MUSCLE ACCUMULATION AFTER ANGIOPLASTY BY AN ANTIBODY TO PDGF [J].
FERNS, GAA ;
RAINES, EW ;
SPRUGEL, KH ;
MOTANI, AS ;
REIDY, MA ;
ROSS, R .
SCIENCE, 1991, 253 (5024) :1129-1132